Pair Name	Cucurbitacin B, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C94]	Bladder cancer		Investigative
Biological Phenomena	Induction-->Autophagic proteins
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Phosphorylation	AKT1S1	hsa84335
	Down-regulation	Phosphorylation	BAD	hsa572
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	BECN1	hsa8678
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Up-regulation	Expression	PSMD9	hsa5715
	Down-regulation	Phosphorylation	RAF1	hsa5894
In Vitro Model	MB49	Bladder transitional cell carcinoma	Mus musculus (Mouse)	CVCL_7076
In Vivo Model	1×10⁶ MB49 cells in 100 μL cold PBS were injected subcutaneously into the right flank of the each C57BL/6 mouse strain.
Result	Our results showed that CuB may be a new agent that can support conventional treatment in bladder cancer. Our study is important in terms of enlightening new pathways and developing new treatment methods in the treatment of bladder cancer.

Pair Name	Cucurbitacin B, Sorafenib
Partner Name	Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP9	hsa842
	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
In Vivo Model	5×10⁶ HepG2 cells were injected subcutaneously into the right flank of nude mice.
Result	Sorafenib and CuB exert synergistic antitumor effects through a pathway that may involve STAT3 phosphorylation, and this may represent a promising therapeutic approach for treatment of HCC.

Pair Name	Cucurbitacin B, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2D10.Z]	Thyroid cancer		Investigative
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BIRC5	hsa332
	Up-regulation	Expression	IREB2	hsa3658
	Up-regulation	Phosphorylation	MAPK3	hsa5595
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	8505C	Thyroid gland anaplastic carcinoma	Homo sapiens (Human)	CVCL_1054
	CAL-62	Thyroid gland anaplastic carcinoma	Homo sapiens (Human)	CVCL_1112
	8505C	Thyroid gland anaplastic carcinoma	Homo sapiens (Human)	CVCL_1054
	CAL-62	Thyroid gland anaplastic carcinoma	Homo sapiens (Human)	CVCL_1112
Result	Synergistic cytotoxicity of doxorubicin with cucurbitacin B is mediated by B-cell chronic lymphocytic leukemia/lymphoma 2 family proteins, survivin, and reactive oxygen species and modulated by Janus kinase 2/signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2 in anaplastic thyroid carcinoma cells.

Pair Name	Cucurbitacin B, Erastin
Partner Name	Erastin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Up-regulation	Expression	IREB2	hsa3658
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	Cucurbitacin B and erastin co-treatment synergistically induced ferroptosis in breast cancer cells via altered iron-regulating proteins and lipid peroxidation

Pair Name	Cucurbitacin B, Gefitinib
Partner Name	Gefitinib
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	PC-9	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_B260
Result	CuB reduced the proliferation of GR PC9 cells by modulating the miR‑17‑5p/STAT3 axis, and may represent a promising potential novel strategy for the reversal of GR.